Manipulating Autophagic Processes in Autoimmune Diseases: A Special Focus on Modulating Chaperone-Mediated Autophagy, an Emerging Therapeutic Target by Fengjuan Wang & Sylviane Muller
REVIEW
published: 19 May 2015
doi: 10.3389/fimmu.2015.00252
Edited by:
Stephanie Hugues,
Université de Genève, Suisse
Reviewed by:
Xinjian Chen,
University of Utah, USA
Willem Van Eden,
Utrecht University, Netherlands
*Correspondence:
Sylviane Muller,
UPR3572 CNRS, Institut de Biologie
Moléculaire et Cellulaire,
Immunopathologie et Chimie
Thérapeutique, 15 Rue René
Descartes, Strasbourg 67000, France
s.muller@ibmc-cnrs.unistra.fr
Specialty section:
This article was submitted to Antigen
Presenting Cell Biology, a section of
the journal Frontiers in Immunology
Received: 02 April 2015
Accepted: 07 May 2015
Published: 19 May 2015
Citation:
Wang F and Muller S (2015)
Manipulating autophagic processes in
autoimmune diseases: a special focus
on modulating chaperone-mediated
autophagy, an emerging
therapeutic target.
Front. Immunol. 6:252.
doi: 10.3389/fimmu.2015.00252
Manipulating autophagic processes
in autoimmune diseases: a special
focus on modulating
chaperone-mediated autophagy, an
emerging therapeutic target
Fengjuan Wang1 and Sylviane Muller 1,2*
1 Immunopathology and Therapeutic Chemistry/Laboratory of Excellence MEDALIS, CNRS, Institut de Biologie Moléculaire et
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Autophagy, a constitutive intracellular degradation pathway, displays essential role in the
homeostasis of immune cells, antigen processing and presentation, and many other
immune processes. Perturbation of autophagy has been shown to be related to several
autoimmune syndromes, including systemic lupus erythematosus. Therefore, modulating
autophagy processes appears most promising for therapy of such autoimmune diseases.
Autophagy can be said non-selective or selective; it is classified into three main forms,
namely macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA),
the former process being by far the most intensively investigated. The role of CMA remains
largely underappreciated in autoimmune diseases, even though CMA has been claimed
to play pivotal functions into major histocompatibility complex class II-mediated antigen
processing and presentation. Therefore, hereby, we give a special focus on CMA as
a therapeutic target in autoimmune diseases, based in particular on our most recent
experimental results where a phosphopeptide modulates lupus disease by interacting
with CMA regulators. We propose that specifically targeting lysosomes and lysosomal
pathways, which are central in autophagy processes and seem to be altered in certain
autoimmune diseases such as lupus, could be an innovative approach of efficient and
personalized treatment.
Keywords: chaperone-mediated autophagy, antigen MHCII presentation, systemic lupus erythematosus, autoim-
mune diseases, lysosomal dysfunction, P140 peptide/Lupuzor
Introduction
Autophagy, an intracellular degradation pathway in which lysosomes play a central role, has been
raised as a hot topic in almost every aspect of cellular processes, including immune responses
and regulation. As it could be expected, therefore, any alteration of autophagy processes can
potentially affect the normal course of cell metabolism and give rise to more or less dramatic
cell malfunctioning. It is precisely what is more and more often emerging from experimental
studies. Nowadays, there is growing evidence reporting the implication of autophagy alteration
in a variety of pathological indications. In particular, some autophagy failures have been sug-
gested or experimentally demonstrated in situation of chronic inflammation and autoimmune
diseases.
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Antigen presentation is a vital step in immune regulation
where antigen-presenting cells (APCs) process antigens into short
peptides, which are then loaded in to major histocompatibil-
ity complex (MHC) class I (MHCI) and II (MHCII) molecules
and presented in this context to T cells. Classical (professional)
APCs include dendritic cells (DCs), macrophages, Langerhans
cells (LCs), and B cells. Beside this canonical antigen presentation
pathway, DCs and non-APCs can acquire MHCI and/or MHCII
molecules from neighboring cells through a pathway of cell–cell
contact-dependent membrane transfer called trogocytosis. These
so-called “MHC-dressed cells” subsequently activate or regulate T
cells via peptide–MHC complexes without requiring any further
processing (1). Exosome-mediated transfer might also contribute
to this process.
Cells use a variety of mechanisms to generate antigens that will
be presented in the context of MHC molecules to the receptor
of T cells (TCR). Among these pathways, autophagy is consid-
ered a major process for the delivery of cytosolic and nuclear
antigens to MHCII molecules in mature or late endosomes, also
known as MIIC compartments (2–7). Abnormalities in antigen
presentation have been proposed to play an important role in
autoimmune diseases. In systemic lupus erythematosus (SLE), for
example, hyperactivity of T cells resulting from panoply of factors
might be related to abnormal antigen presentation by APCs (8,
9). Control of the autophagy pathway is thus critical, and phar-
macological intervention targeting specific steps of this complex
process could be determining at reprograming some dysfunction
of the immune system occurring notably in inflammatory and
autoimmune diseases (10–16).
Three major forms of autophagy have been found ubiquitously
in eukaryotic cells, namely microautophagy, macroautophagy,
and chaperone-mediated autophagy (CMA). Microautophagy is
featured by a direct engulfment of cytosolic portions through
lysosomal invagination. It is the least studied process among the
three processes, yet microautophagy-like process has been shown
to deliver cytosolic proteins to late endosomal compartments in
DCs and might represent an important alternative route for anti-
gen presentation (17, 18). This microautophagy-like degradation
pathway does not depend on the canonical autophagy machinery
and is distinct from CMA.
Macroautophagy is the most intensively studied form of
autophagy and the vastmajority of currently published data on the
role of autophagy in antigen presentation result from investigation
based on this basic autophagic process. In the macroautophagy
pathway (Figure 1), double-membrane structures are generated
to engulf whole cytosolic components, including organelles, and
form autophagosomes. The latter then use microtubular tracks
to encounter and fuse with lysosomes/late endosomes to form
vesicles called autolysosomes where lumenal hydrolytic enzymes
degrade cargo (microtubules have to be acetylated to allow fusion)
(19). Initial description of macroautophagy process referred to
random sequestration of cargo only. Nowadays, we know that
macroautophagy can also occur in a more selective manner.
Thus, mention may be made of aggrephagy (for aggregated pro-
teins), mitophagy (mitochondria), ribophagy (ribosomes), pex-
ophagy (peroxisomes), reticulophagy (endoplasmic reticulum,
ER), lipophagy (lipid droplets), and xenophagy (pathogens),
showing that in factmacroautophagy participates in a highly selec-
tive and tightly regulated process of substrate delivery (20–22).
Direct evidence has been reported that endogenous antigen pre-
sentation depends on macroautophagy (3, 23–26), and activation
of macroautophagy could facilitate presentation of intracellular
peptide on MHCII molecules (2). In DCs used as APCs, the
autophagy-related gene (ATG) 5, a key autophagy gene, seems to
be required for antigen presentation (26). While mice with DC-
conditional deletion in Atg5 displayed no development defect,
they showed, however, important failure mounting a normal
T-cell response linked to improper processing and presentation
of cytosolic antigens on MHCII molecules.
The third main type of autophagy, CMA (Figure 1), is a
process where client proteins containing specific motifs related
to KFERQ (present in about 30% of soluble cytosolic proteins)
(27) are selectively recognized by the cytosolic chaperone pro-
tein HSPA8/HSC70 present in a co-chaperones-rich complex that
delivers them to the lysosomemembrane. Examples of such client
proteins/substrates are glyceraldehyde 3-phosphate dehydroge-
nase, the E3 ubiquitin ligase ITCH, the calcineurin inhibitor
RCAN1, the neuronal alpha-synuclein and tau proteins, galectin-
3, andHSPA8 (28–30). The complex containingHSPA8 associated
to the substrate then binds to the so-called lysosomal-associated
membrane protein type 2A (LAMP-2A), acting as a monomer at
this stage. LAMP-2A (but not LAMP-2B or LAMP-2C, or HSPA8)
is exclusive for CMA. The binding of substrates to LAMP-2A leads
to its multimerization, likely with the help of lysosomal HSP90
protein; the substrates undergo unfolding and reach the lysosome
lumen through the LAMP-2A-enriched translocation complex
with the aid of lysosomal HSPA8, where they are degraded by
lysosomal proteases. LAMP-2A multimers then disassemble and
degrade for the next cycle of CMA (28). This process, which
is finely regulated (29), is carried out at basal level and can be
activated under prolonged starvation and other stresses. It works
then as an alternative energy sources and quality control to remove
damaged proteins upon stress. CMA dysfunction (enhancement
or slowdown) seems to directly or indirectly contribute in many
diseases including neurodegenerative pathologies, metabolic dis-
eases, and cancer (31–34). Recent evidences from our laboratory
and others strongly support the importance of CMA in antigen
presentation and pathological conditions, especially in autoim-
munity.
The role of macroautophagy in antigen presentation has been
described extensively in comprehensive reviews (7, 16, 35–41).
Original data also accumulated supporting a central role for
macroautophagy in both innate and adaptive immune responses,
which greatly influence antigen presentation (42–45). Our inten-
tion herein is therefore to orientate our discussion on recent
findings supporting the prominent role of autophagy in anti-
gen processing and presentation, with a particular focus on
CMA and autoimmunity. A special emphasis will be given on
lupus, as several recent studies have provided novel results that
shed new light on this syndrome and may have important ther-
apeutic issues. The topic of this review will also address in
lupus the possible inherent dysfunction of lysosomes, a cen-
tral organelle that has been seldom examined in autoimmune
settings.
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FIGURE 1 | Cross-talk between macroautophagy and CMA in immunity.
In macroautophagy (left, light pink region), amphisomes and autophagosomes
that contain elements of a cell’s own cytoplasm, fuse with lysosomes to form
autolysosomes in which autophagic substrates are degraded. In CMA (right,
light blue region), however, cytosolic substrates that possess a KFERQ-like motif
are recognized by HSPA8 and directly delivered to lysosomal receptor LAMP-2A
together with other co-chaperones followed by degradation into lysosomes. In
APCs, lysosomal compartments (lysosomes and autophagosomes) can further
derive to MIIC. In this compartment, antigenic peptides are loaded into MHCII
molecules, which can thus be delivered to the PM and recruit/activate CD4+
T cells. Clearly lysosomes are the central player for antigen presentation and
immunity, and any dysfunction of lysosomal can lead to immune defects and to
autoimmunity in particular. If selective, targeting lysosomal pathways (such as
autophagic pathways) could thus become a strategy of choice to treat
autoimmune patients. Macroautophagy and CMA are normally kept in a delicate
balance and are intrinsically linked. Therefore, cautions need to be taken when
intervening on one of the two pathways in autoimmune therapy, as the other
could be potentially affected. APCs, antigen-presenting cells; CMA,
chaperone-mediated autophagy; LAMP-2A, lysosomal-associated membrane
protein type 2A; ly-HSPA8/ly-HSP90, lumenal (lysosomal) HSPA8 and HSP90;
MHCII, major histocompatibility complex class II; MIIC, MHC class II
compartment; PM, plasma membrane; TCR, T-cell receptor.
CMA and Antigen Presentation
While the implication of macroautophagy in antigen presentation
has been extensively investigated in independent laboratories, that
of CMA in this process has seldom been studied. Experimental
data supporting the view of a direct implication of CMA in antigen
presentation have been provided by Blum and collaborators who
demonstrated that bymanipulating the expression of LAMP-2Aor
HSPA8 (the two key components of the CMA pathway) in stable
human B-cell line, enhanced or reduced cytoplasmic autoantigen
presentation could be observed (4). Silencing total cellular LAMP-
2 levels reduced the MHCII presentation of the endogenous anti-
gen glutamate decarboxylase (GAD) presented in the context of
HLA-DR4 (presentation of exogenous antigens, such as human
serum albumin, was also decreased in cells with reduced LAMP-
2A and LAMP-2B levels). Overexpression of LAMP-2A isoform
led to an increased presentation of endogenous GAD but not
of exogenous antigens. Overexpression of LAMP-2B, however,
had no effect on cytoplasmic or extracellular antigens. Similar
observations were made using cells in which the levels of HSPA8
expression were modified. These data suggest a role for CMA in
endogenous MHCII antigen presentation. Further experiments
using a set of endogenous antigens corresponding or not to CMA
substrates should consolidate these findings.
It is not only in antigen presentation that CMA plays impor-
tant role, but also in T-cell regulation. Recent data have revealed
that CMA is an essential regulatory element of T-cell activation
through the targeted degradation of negative regulators of TCR
signaling, namely the ubiquitin ligase Itch and the calcineurin
inhibitor RCAN1 (30). This study provides the first evidences that
TCR engagement induces CMA, likely through the generation
of reactive oxygen species (ROS), a CMA inducer. Deletion of
LAMP-2A gene abolishes in vivo T-cell response to immunization
or infection.
CMA Alteration in Autoimmunity
In immunity, autophagy has emerged some years ago as a pro-
cess, the deregulation of which could lead to a breakdown of
tolerance to self and autoimmunity [reviewed in Ref. (16, 46–51)].
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Following the discovery that several ATGs could be associated
to autoimmune syndromes, e.g., ATG5, PR domain zinc finger
protein 1 (PRDM1; also known as BLIMP-1), DNA-damage reg-
ulated autophagy modulator 1 (DRAM1) in SLE patients (52–
56), or ATG16L1 and immunity-related GTPase M (IRGM) in
Crohn’s disease and ulcerative colitis (57–61), further studies, at
the cellular and molecular levels, were undertaken. Alterations
of macroautophagy were effectively found to occur in several
immune cell subtypes from patients and model mice with lupus,
in T cells (62, 63) and later on in B cells (64) and macrophages
(65). Macroautophagy defects were also observed in rheumatoid
arthritis (RA) (66, 67), multiple sclerosis (MS) (68), and type-I
diabetes (69, 70), for example [reviewed in Ref. (71)].
Although most of these observations would require deeper
investigations to reinforce the molecular and cellular mechanisms
that underline the observed autophagy failures, the link exist-
ing between inflammatory autoimmune diseases and macroau-
tophagy seems to be well established. It is far to be the case
with CMA. Nowadays, the effect of CMA activity on human
autoimmunediseases remains largely unknown. This lack of infor-
mation likely results from the fact that murine models which
display a genetic background of autoimmunity and that are further
deleted for CMA markers LAMP-2A and HSPA8 could not be
generated until now and that CMA-specific inhibitors are not
available. Known data were obtained using a spontaneous murine
model of autoimmunity, the MRL/lpr mouse that develops a
strong lupus-like disease characterized by lymphadenopathy due
to an accumulation of double negative CD4 CD8 CD3+B220+
T cells (72, 73). These mice (both females and males) display
an accelerated mortality rate and produce lupus-specific autoan-
tibodies [reacting with double stranded (ds) DNA, nucleosome,
and ribonucleoprotein (RNP) Sm antigens]. In addition, they
possess large amounts of immune complexes and cryoglobulins
in their serum as well as, rather typical of RA, high incidence and
titer of rheumatoid factors. The accelerated lupus-like phenotype
observed in MRL/lpr results from a recessive autosomal mutation
called lymphoproliferation (Lpr) that alters transcription of the
FAS receptor (74).
MRL/lpr mice present many immune defects attributed to Fas
deficiency, notably in CD4+ T cells and B cells. In addition to
these defects that have been extensively investigated over years,
we showed recently that the CMA pathway is deregulated. Both
LAMP-2A and HSPA8 CMA markers were found to be over-
expressed in splenic MRL/lpr B cells (75, 76), suggesting strongly
that in this setting, there is a change in CMA activity. At this stage,
it is not known if this alteration affects all or a subset only of
lysosomes in MRL/lpr B cells and if other APCs are also affected.
Themolecularmechanisms that are implicated in these changes of
expression are not known either but seem to be different.Whereas
HSPA8 expression correlates with increased mRNA expression in
MRL/lpr splenocytes, variation in mRNA were not observed for
LAMP-2A (75, 76). In any event, the results that emerge from
these two studies are pivotal since as detailed above, CMA may
contribute to antigen presentation, and in the current setting the
amount and/or the diversity and/or the nature of peptides that are
loaded to MHCII molecules and presented to autoreactive CD4 T
cells could be largely affected.
Cross-Talk Between Macroautophagy and
CMA in Autoimmunity
Althoughmacroautophagy andCMAare clearly distinct pathways
with their proper regulation systems, they are closely linked de
facto at the late fusion stages when the autolysosomes are formed
from amphisomes and lysosomes or from autophagosomes and
lysosomes (Figure 1). A cross-talk occurs between macroau-
tophagy and CMA during starvation (77, 78). Macroautophagy is
activated shortly after starvation and reaches its maximum level
around 4–6 h. When CMA is stimulated (gradually after 8–10 h
of starvation and for up to 3 days) (77), macroautophagy is first
induced and then declines. It has also been demonstrated in these
studies that inhibiting CMA by depletion of LAMP-2A induces
macroautophagy and vice versa that blockage of macroautophagy
via genetic and pharmacological approaches could activate CMA.
On a functional point of view, there is clearly a kinetic and tempo-
ral balance between the two processes (79). This important aspect
has to be taken into account in the development of molecules
designed to specifically regulate one particular pathway.
Lysosomal Dysfunction in Autoimmune
Diseases
Endo-lysosomal compartments play vital roles in immune regu-
lation. Their functions include trafficking, maturation of MHCII
complexes, antigen processing and presentation, and signal trans-
duction (80). The biological functions of lysosomes are medi-
ated by various enzymes (glucosidases, proteases, and sulfatases)
that are contained in their lumen and constituents of lysosomal
membrane. The physiological environment that endosomes and
lysosomes encounter (pH, amino acids concentration, ROS, Ca2+
content, lipid composition, and membrane potential) is essential
for their proper functioning. A number of adverse elements can
affect them, potentially leading to abnormal antigen presenta-
tion and altered immune responses (80–82). The central roles of
lysosomes in immunity and autoimmunity are discussed below.
The Early Hypothesis on “Lysosomal Fragility” in
Autoimmune Diseases
The first hypothesis linking lysosomes and autoimmune phenom-
ena was proposed by Weissmann and Thomas as early as in 1962.
They proposed that “lysosome fragility” could be related to SLE
following a rational reflection on two phenomena, namely (a)
that ultraviolet light can exacerbate SLE manifestation in patients
and (b) that lysosomes are highly sensitive to ultraviolet light
both in vitro and in vivo (83). Although it was a genuine idea,
this avenue has not been pursued. It is much later only, that
experimental investigations revisited this hypothesis leading to
the suggestion that lysosomal enzymes that are released from
“fragile” lysosomes might be autoantigens in SLE (84). Detailed
studies on the fragility of lysosomes in SLE and other autoimmune
diseases are still relatively scarce and these assumptions remain
to be experimentally consolidated. Current studies whose task is
to link lysosomal dysfunctions and autoimmune diseases mainly
focus on the activities of lysosomal proteases and lysosomal-
related pathways in these indications.
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Lysosomal Proteases in Antigen Presentation
and Autoimmunity
Antigen presentation relies on the lysosomal proteases. Numerous
studies have been carried out to identify the specific proteases
that are involved in the MHCII antigen presentation pathways
(85–88). Lysosomal proteases include cysteine cathepsins families
(B, C, F, H, K, L, O, S, V, W, and X), aspartyl cathepsins (D
and E), and serine cathepsins (A and G) as well as asparagine
endopeptidase (AEP). They are synthesized under the form of
zymogens in the ER and transported to the Golgi apparatus where
they are modified by the addition of mannose-6-phosphate. This
tag facilitates their transportation to lysosomes where they get
activated by the low-pH endo-lysosomal environment. Lysosomal
proteases exhibit various functions in immunity, such as process-
ing of the invariant chain (Ii), which is required for thematuration
of MHCII complexes, proteolytic processing of antigen, and TLR-
receptor signaling (88, 89).
The maturation of MHCII complexes is dependent on the pro-
cessing of invariant chain Ii to Class II associated invariant chain
peptide (CLIP-fragment). The invariant chain Ii is first degraded
into a 22-kDa leupeptin-induced protein (LIP) intermediate, then
to a 10-kDa small-leupeptin-induced protein (SLIP) intermediate
and finally to theCLIP-fragment. The rate-limiting step is the final
processing from SLIP to CLIP, which has been identified to be
dependent on cysteine protease-cathepsin S. Inhibition of cathep-
sin S by either genetic knock-out or chemical inhibitors leads to
accumulation of SLIP intermediates in B cells, macrophages, DCs,
and T cells that can also express functional MHCII molecules (90,
91). Cathepsin L (92), V (93), and F (94) have been suggested to
be also involved in this multistep process.
As the executors of antigen processing, lysosomal proteases
represent “double-edged swords,” as they can either generate anti-
genic epitopes (in favor of their presentation) or destroy some epi-
topes (acting therefore against their further presentation). Lysoso-
mal proteolysis is often assumed to favor production of ligands for
MHCII molecules. Blocking lysosomal function and abolishing
activity of lysosomal proteases by lysosome alkalization, for exam-
ple, decrease antigen presentation (95–98).Mice deficient inman-
nose 6-phosphate, the tag that targets newly synthesized lysosomal
proteases from ER to lysosomes (see above), show significant
loss of various lysosomal proteases in B cells. This deficiency
in lysosomal proteases leads to impaired antigen processing and
presentation (99). In most cases, the processing of endocytosed
antigens is not specific, as the cleavage site is determinedmainly by
its accessibility to the active site of proteases. Nevertheless, some
studies have also shown that presentation of a particular epitope
requires a certain type of lysosomal proteases, such as the essential
role of AEP for tetanus toxin processing in human APCs (100).
Intriguingly in the case where lysosomal proteases play a
destructive role for the antigen epitopes, limited lysosomal prote-
olysis still favors their presentation. Delamarre et al. demonstrated
that bovine pancreatic ribonuclease RNase A is more immuno-
genic than its variant RNase S, which is structurally and enzy-
matically identical to RNase A, but more susceptible to lysosomal
proteolysis (101). This suggests that in some cases, reducing the
susceptibility of antigens to lysosomal proteolysis can nevertheless
enhance their immunogenicity. It is noteworthy that macrophages
are rich in lysosomal proteases capable of rapidly destroying inter-
nalized antigens whereas DCs and B lymphocytes, in comparison,
are poorer in proteases, which makes them rather in charge of
antigen processing and presentation (102). It is not clear whether
this limited proteolysis is specific to certain proteases/antigens.
Absence of one protease can also increase the presentation of
certain epitope, as shown in the case of myelin basic proteins
and myoglobin, which are readily presented by human APCs that
lack AEP, and by mouse APCs that lack cathepsin D (103, 104).
The dual role of lysosomal proteases in antigen presentation is
therefore complex and still requires further elucidation. This ques-
tion remains central as the final levels of the presented peptides
(together with an array of co-stimulatory signals) determine the
ultimate immune response, namely tolerance or autoimmunity.
Most importantly also, lysosomal proteases are known acti-
vators of endo-lysosomal pattern sensing receptors TLRs. Thus,
endo-lysosomal proteases are found to activate TLR9 through the
cleavage of its N-terminal region, which transforms the receptor
to its signaling-active form. TLR3 and TLR7 have been shown to
be activated similarly (105–107). Chemical inhibition and gene
knock-out studies have indicated that AEP and cathepsin K are
specific for TLR processing (108, 109).
Due to the central roles of lysosomal proteases in antigen pre-
sentation, maintenance of their activities is essential for immune
responses. Perturbation of their activities has been found to be
related to autoimmune diseases. For example, the expression levels
and activities of cathepsins S and H have been shown to be
increased in lacrimal glands of mouse models of Sjögren’s syn-
drome (SS) (110); tear cathepsin S has been further character-
ized in SS and proposed as a candidate biomarker for SS (111).
Cathepsin D-like activity has been shown to be raised in the SLE
patients’ serum, and at a lower extend in the serum of patients
with progressive systemic sclerosis, chronic glomerulonephritis,
and glomerulonephritis with nephrosis syndrome (112). Studies
dealing with the expression levels and activities of lysosomal pro-
teases still remain limited. Theymight have important application
as it has been shown, for example, that cathepsin S inhibition could
suppress lupus nephritis and other signs of the lupus disease (113).
Omics studies would be needed to further identify deregulated
expression of lysosomal proteases in autoimmune diseases.
Lysosomal pH is Essential for Immune Regulation
Themaintenance of proper lysosomal functions is not only related
to expression levels of lysosomal proteases, but also to their prote-
olytic activities, which largely depend on lysosomal pH environ-
ment. Most lysosomal proteases show their optimal activity in the
acidic environment in lysosomes (pH 4.0–5.0). The acidification
of lysosomes relies on the vacuolar H+-ATPase, a transmembrane
multimeric protein complex, which pumps protons from the
cytosol into the lysosomal lumen against their electro-chemical
gradient by using energy from ATP hydrolysis (114, 115). Alter-
ation of lysosomal pH, particularly lysosomal alkalization, was
shown to contribute to the pathologies in several chronic diseases
(116, 117).
With a ratiometric fluorescent dye LysoSensor Yellow/Blue that
is specifically designed for lysosomal pH measurement (118), we
recently demonstrated that in the spleen, MRL/lpr B cells exhibit
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considerably higher pH than healthy CBA/J mice B cells, with
mean lysosomal pH values of 5.4 and 4.3, respectively (Figure 2A)
(76). This raised pH that can reach values close to 6 in some
MRL/lpr mice, might lead to a decreased activity of lysosomal
proteases. As discussed above, limited antigen processing can
possibly result into enhanced immunogenicity (101). Altogether,
these observationsmight explain at least in part the over-reactivity
of peptide-reactive T cells to unique peptides presented by APCs
in MRL/lpr mice (78, 119). Moreover, the increase of lysosomal
pH in lupus B cells could affect the CMA process. The stability of
lumenal HSPA8 is effectively superior when pH values are around
5.2–5.5 (78). This might explain in part the hyperactivity of CMA
recently demonstrated inMRL/lpr B cells (76). At this stage, much
more investigation would be required to consolidate the link that
may occur between a higher lysosomal pH and a hyperactivity
of B cells in MRL/lpr mice. Likely due to the lack of convenient
and highly effective probes for lysosomal pH measurement, few
data are available in the literature in terms of perturbation of
lysosomal pH in autoimmune diseases. Our pH measurement in
the MRL/lpr mice model suggests that increase of lysosomal pH
is an important aspect of lysosomal malfunction that needs to be
evaluated in SLE and other autoimmune diseases.
FIGURE 2 | Alteration of lysosomal functions in autoimmune
diseases. (A) The pH values of lysosomes are compared in the
splenocytes (mainly B cells) of three healthy CBA/J mice and three MRL/lpr
lupus-prone mice. Splenocytes were stained with LysoSensor Yellow/Blue
DND-160, followed by ratiometric measurement at excitation wavelength
360 nm and emission wavelengths both 460 nm (blue) and 535 nm (yellow).
The blue/yellow ratio was calculated after subtracting the background
fluorescence. A standard curve of blue/yellow ratio versus pH was
performed meanwhile in Raji cells by clamping their lysosomal pH in buffers
with a series of pH and ionophores. The pH values of lysosomes were
calculated from the standard curves. The error bars are standard
deviations from three replicates. (B) The total volumes of lysosomal
compartments are compared in the splenocytes from CBA/J and MRL/lpr
mice (four mice of each strain) by LysoTracker Green staining DND-26 and
flow cytometry measurement. The fold change of LysoTracker Green mean
fluorescence intensity is plotted in the graph [modified from Ref. (75)].
(C) Schematic illustration of the differences between lysosomal functions in
CBA/J and MRL/lpr B cells and the impact in autoimmunity (hypothetical
scenario). In CBA/J mice and basal conditions, most lysosomes in B cells
are CMA ; they show physiological pH (namely ~4.5) and a basal content
of LAMP-2A and ly-HSPA8 CMA markers. In contrast, in MRL/lpr B cells,
beside lysosomes that are not affected and remain mostly CMA , subsets
of lysosomes exhibit higher pH values (>5.0); in those B cells, the volume
of lysosomal compartments is higher in average, likely due to increase in
their sizes and/or numbers and the expression levels of lysosomal
LAMP-2A and HSPA8 are elevated, indicative of higher CMA activity
(CMA+ lysosomes). The alterations of lysosomes and CMA activity might
both lead to higher antigen presentation at the B-cell surface (B cells serve
as efficient APCs in lupus) and consequently hyperactivity of autoreactive
CD4+ T cells. CMA, chaperone-mediated autophagy; CMA+/CMA ,
CMA-active/-inactive lysosomes; F, female; LAMP-2A,
lysosomal-associated membrane protein type 2A; ly-HSPA8, lumenal
(lysosomal) HSPA8; M, males; MIIC, major histocompatibility complex class
II compartment; PM, plasma membrane; TCR, T-cell receptor; w, weeks.
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Beside the increased lysosomal pH, an augmentation of total
volume of acidic compartments was also observed in B cells from
MRL/lprmice (Figure 2B) (76). This resultwas obtained following
staining of splenocytes by LysoTracker Green and FACS analysis.
A similar observation was published using MRL/lpr liver Kupffer
cells (120). This finding might be related to an increased size
of lysosomes and/or an increase of lysosomal number, which
needs to be further investigated. One can hypothesize that lysoso-
mal biogenesis could be altered in autoimmune diseases leading
to hyperactivity (quantitative or qualitative/selective) of antigen
presentation in APCs that can deregulate the responsiveness of
autoreactive CD4+ T cells (Figure 2C).
Lysosomal Storage Diseases and Autoimmune
Responses
Lysosomal storage diseases (LSD) diseases are genetically inher-
ited metabolic disorders due to defects in lysosomal enzymes that
are essential for the metabolism of proteins, lipids, and other cell
components. The accumulation of non-degraded materials inside
lysosomes can lead to their dysfunction. Some immune system
abnormalities, either suppression or hyperactivity, associated with
LSDs have been described (121, 122). Hyper-responsiveness of
immune cells was notably observed in LSDs such asmucopolysac-
charidosis IIIB (MPS IIIB), GM2 gangliosidosis, globoid cell
leukodystrophy, Niemann-Pick type C1, and juvenile neuronal
ceroid lipofuscinosis [reviewed in Ref. (121)]. In MPS IIIB,
a pathogenic autoimmune response directed to central ner-
vous system (CNS), components independent of LSD pathol-
ogy were identified (123). MPS IIIB is characterized by autoso-
mal recessive defects in α-N-acetylglucosaminidase, a lysosomal
enzyme, which degrades heparin sulfate (HS), a glycosaminogly-
can (GAG), which is important for biological homeostasis (it is
known in particular to modulate the sensitivity of T cells and
APCs upon stimulation). Aberrant GAG metabolism has been
described to be associated to several autoimmune diseases, such as
RA, scleroderma, and SLE (124–126). Consistently in their MPSI-
IIB mouse model, Killedar et al. observed enhanced autoimmune
CNS antigen presentation (123). Although a direct link between
LSDs and autoimmune diseases is not clearly established, it is
tempting to take into account the central role of lysosomes in
autoimmunity when considering LSDs.
It should be added that a number of studies have highlighted
some defects in the autophagy-lysosome process in LSDs and
relevant murine models (122, 127–130) with notably, some failure
in the autophagosome clearance. These features led Lieberman
and colleagues to conclude that LSDs could be seen primarily as
“autophagy disorders” (127).
Therapeutic Molecules that Target
Autophagy and Lysosomes
Due to the essential role of lysosomes in immunity, modulating
lysosomal functions has been put forward as a right therapeutic
strategy for inflammatory diseases (16, 131, 132). An established
way of lysosomal intervention is through inhibition of lysosomal
acidification. In their pioneering work published more than three
decades ago, Ziegler and Unanue demonstrated the inhibitory
effect of chloroquine (CQ) on antigen presentation to T cells
(133). In the context of autoimmune indications, mention should
thus be made of drugs that increase lysosomal pH such as CQ
and hydroxychloroquine (HCQ; plaquenil™), which have been
shown to be effective in SLE (134–137), SS (138), RA (139,
140), and a rat model of MS, the experimental autoimmune
encephalomyelitis (141). Note that nowadays, the mechanism of
action of CQ/HCQ is still a matter of debates. Any direct effect
of CQ/HCQ on CMA process was not described and it is not
known if these molecules play an effect on CMA-active and/or -
inactive lysosomes. Data are also lacking regarding their possible
effect on the lysosomal pH of various immune cells when used
at pharmacological concentration range. It is indeed perplexing
whether and how CQ/HCQ could further enhance the lysosomal
pH in the splenocytes (primarily B cells) of MRL/lpr mice that
already exhibit a higher lysosomal pH than that measured in
CBA/J splenocytes. It is even unclear if efficacy of CQ and HCQ
in SLE, SS, and RA results solely from their ability to increase
the lysosomal pH, as this family of molecules exerts very diverse,
possibly indirect, effects (142). The lack of selectivity of a drug
generally originates undesirable secondary effects. CQ is effec-
tively known to exhibit retinal toxicity. Serious vision loss that is
usually irreversible has been observed. Although HCQ generates
much less side effects, the risk of HCQ toxicity rises to nearly
1% with a total cumulative dose of 1.0 g, which corresponds to
5–7 years of normal use. Annual ophthalmologic examinations
are therefore recommended 5 years onward under HCQ therapy,
and in some cases before, if there are known risk factors (143).
A number of HCQ analogs and mimics have been tentatively
designed that keep the molecule activity without adverse effects.
Ongoing research should provide such safe molecules in the
future.
Besides CQ and HCQ, other alkalinizing lysosomotropic drugs
that affect lysosome function have been described. They are
amodiaquine (Camoquin™, Flavoquine™), a 4-aminoquinoline
compound related to CQ, and azithromycin (Zithromax™,
Azyth™, or Azithromycin™), for example. The latter, a potent
macrolide antibiotic, is notably used for treating chronic inflam-
matory lung diseases, such as cystic fibrosis (CF). Long-lasting
use of azithromycin by CF patients can lead to deleterious effects,
notably some infections by non-tuberculous mycobacteria. It
was found that azithromycin, which affects lysosome acidifica-
tion, provokes a blockade of autophagosome clearance and a
much weaker intracellular killing of mycobacteria (144). The
MF6p/FhHDM-1 major antigen secreted by the trematode par-
asite Fasciola hepatica has also been reported to suppress anti-
gen processing and presentation selectively in macrophages by
inhibiting vacuolar ATPase activity, which consequently reduces
lysosomal acidification (132).
The second approach to modulate lysosomal function is by
using protease inhibitors. Inhibition of lysosomal acidification
(such as by HCQ) can inhibit lysosomal protease activity, though
without selectivity. Some inhibitors specific for individual lyso-
somal proteases were developed and might have some promise
for therapy of autoimmune diseases. Due to its key role in the
maturation of MHCII complexes, together with the fact that its
expression and/or activity has been shown to be increased in
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some autoimmune diseases (see above), cathepsin S, in partic-
ular, represents an attractive target for such therapeutic options
(88, 145). The orally available cathepsin S inhibitor RO546111
was shown to reduce the activation of splenic DCs and the
subsequent activation of CD4+ T cells, to diminish hypergam-
maglobulinemia and anti-dsDNA antibody levels and prevent
lupus nephritis progression inMRL/lpr lupusmice (113). Cathep-
sin S inhibitor Clik 60, a molecule developed with the help
of computer-graphic modeling method based on the stereo-
structure, shows suppression of autoimmunity in a murine model
for SS (146). New classes of cathepsin S selective inhibitors
have been developed (88, 147), and some of them, such as
RWJ-445380 and CRA-028129, are currently evaluated in late
stage clinical trials for the treatment of RA and psoriasis. The
activity of cathepsin K inhibitors, such as blicatib, relacatib,
and odanacatib, was also investigated (88). In a phase-III clin-
ical trial, it was observed a significant reduction of fractures
in post-menopausal women under odanacatib (148). Treatment
of CA-074, a cathepsin B inhibitor, was also reported to sup-
press autoimmune responses in a mercury-induced autoimmune
mouse model (149). Targeting endo-lysosomal proteases remains,
however, a difficult pharmacological task due to the fact that
single proteases can have multiple functions (88). Furthermore,
there is a cross-talk between proteases, and inhibiting one spe-
cific protease can up-regulate or down-regulate another one.
Many more studies are therefore required before pharmacological
interventions based on this strategy can be generalized with-
out risk.
The third strategy to target lysosomes is through modulation
of autophagic pathways. Several drugs used experimentally or
currently under preclinical trials for SLE, such as glucocorticoids,
HCQ, rapamycin, P140 (Lupuzor™), bortezomib (Velcade™; the
first approved proteasome inhibitor), vitamin D, and cyclosporine
A have been found, sometimes incidentally and belatedly, to act as
potent activators or inhibitors of autophagy processes (16). The
very large majority of these molecules interfere with macroau-
tophagy and in general they also act on other, non-autophagic
targets (10–16, 51, 150). Since, as detailed above, macroautophagy
and CMA are maintained in a finely regulated balance (this is
also the case between autophagy and apoptosis or autophagy and
the proteasomal system, for example), discontinuing one pro-
cess could lead to abnormality of the other. Thus, again, along
with other strategies described above, pharmacological interven-
tions targeting autophagy pathways require advancedmechanistic
investigations to be made.
The Phosphopeptide P140, a Potent
Immunomodulator of the T-Cell Response
in SLE
Among the numerous molecules claimed to activate or inhibit
autophagy, very few in fact primarily target the CMA pathway
(151, 152). Noteworthy also is the recognition that some small
molecules initially described as specific CMA modulators have
since proven to exhibit other activities, which somewhat dimin-
ishes their initial interest (29, 153). In this context, the remarkable
properties of the so-called peptide P140must be highlighted. This
peptide, which significantly reduces the biological and clinical
defaults of SLE in patients and delay mortality of treated MRL/lpr
mice, binds and co-localizes in vivo with HSPA8, a major chap-
erone of the CMA and macroautophagy processes (154). P140
is a 21-mer linear peptide (sequence 131–151) derived from the
small nuclear RNP U1-70K. A phosphoserine residue was intro-
duced at position 140 during its chemical synthesis (hence its
name). In a multicenter, randomized, placebo-controlled phase
IIb study, P140/Lupuzor was safe andmet its primary efficacy end
points in lupus patients (155). These results confirm previous data
generated in MRL/lpr lupus-prone mice in which the preclinical
studies were performed (156, 157) and those obtained in an open
multicenter phase IIa clinical study in which 20 lupus patients
were enrolled (158). A phase-III clinical trial will start shortly in
North America and West Europe.
Recently, the pathway taken by the peptide P140 intracellularly
and its potential mode of action have been elucidated (76). In
MRL/lpr B cells, the phosphorylated peptide P140, but intrigu-
ingly not the non-protective unphosphorylated peptide, uses the
clathrin-dependent endocytosis pathway to reach and accumulate
into lysosomes. Based on in vitro data, it is assumed that in
the lysosomal lumen, P140 compromises CMA, at least in part,
by disruption of the lysosomal lumenal HSPA8 heterocomplexes
containing HSP90. The consequence of this inhibitory effect on
CMA may be a slowing-down or a qualitative change of cellular
autoantigen loading toMHCII molecules and as a result, a weaker
priming of autoreactive T cells. This effect potentially ends up by
a beneficial reduction of autoreactive B-cell proliferation and dif-
ferentiation into deleterious autoantibody-secreting plasma cells,
leading to an improvement of the autoimmune status observed in
patients with SLE (76).
This mechanism of action has been substantiated by in vitro
experiments showing a direct effect of P140 on the CMA pathway
(Figures 3A–C) in NIH3T3 cell line. It is also supported by in vivo
data demonstrating that upon treatment of MRL/lpr mice with
the P140 peptide, the levels of two key CMA components, namely
LAMP-2A andHSPA8,which are over-expressed in lupusmice are
significantly decreased in B cells of treated mice (Figures 3D–F)
(75, 76). Other lysosomal proteins, such as cathepsin L and to
a lower extent LAMP-1, follow the same trend. It should be
noted that the mechanisms that modulate HSPA8 and LAMP-2A
changes are different. Whereas HSPA8 protein expression corre-
lates with its increased mRNA expression in MRL/lpr splenocytes
(75), variations in mRNA were not observed for Lamp-2a (76). It
is therefore possible that a modification in the stability of LAMP-
2A occurs in the lupus model, and since HSP90 is involved in the
stabilization of LAMP-2A (159), the weaker stability of LAMP-
2A could in fact result from the effect of P140 with the HSPA8
heterocomplex containingHSP90. Among the other experimental
data that reinforce the proposed mechanism are the findings that
upon treatment of MRL/lpr mice with P140 peptide, there is a
decreased expression of MHCII molecules (75), a much weaker
reactivity of peripheral T cells toward peptides known to encom-
pass T-cell autoepitopes (160), and lower levels of anti-dsDNA
antibodies that are markers of the lupus disease (156). Most inter-
estingly, compared to MRL/lpr mice that received saline, P140-
treated MRL/lpr mice normally responded to a viral challenge
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FIGURE 3 | P140 peptide, an immunomodulator that acts by inhibiting
the CMA pathway. (A–C) P140 peptide (30µM) but not the truncated
131–148 P140 peptide analog (30µM) used as control decreases CMA activity
in a dose-dependent fashion. NIH3T3 cells stably expressing the
photoswitchable CMA reporter KFERQ-PS-Dendra were photoswitched and
maintained in serum-supplemented media (CMA ) or serum-supplemented
media with PQ (CMA+), which induces CMA by generating mild oxidative
stress. Cells were further exposed to P140 or control peptide 131–148 P140 at
the indicated concentrations for 12 h. The fluorescence of CMA reporter was
measured with high content analysis and representative images are shown in
(A) [yellow=KFERQ-PS-Dendra; blue=DAPI]. The quantification was done by
calculating the average number of KFERQ-PS-Dendra puncta in nine different
fields (approximately 700 cells per condition) and divided by untreated control as
the fold change of CMA activity and shown in (B) for cells treated with P140 and
(C) with 131–148P140 for indicated concentrations. (D) The surface expression
of HSPA8 was measured in B cells of 6- and 12-week-old CBA/J and MRL/lpr
by flow cytometry. The fold changes were plotted by dividing the mean
fluorescent intensity values of HSPA8 staining by those of isotype staining.
(E) The surface expression of HSPA8 was measured in B cells of untreated
MRL/lpr mice or of MRL/lpr that received six intravenous injections of peptide
(100µg P140/mice/injection) at daily intervals. The arbitrary geometric mean (G
mean) values of HSPA8 fluorescence were plotted for MRL/lpr B cells with or
without P140 injection. The error bars are standard deviation from three
replicates. (F) The expression levels of LAMP-2A in purified B cells from CBA/J
mice, untreated MRL/lpr mice (11–13-week-old), MRL/lpr mice that received
one injection (and cells were collected 5 days later) or six injections
(100µg/mice/injection) of P140 peptide at daily intervals, were assessed by
western blot and quantified by densitometry. ACTB, actin beta; CMA,
chaperone-mediated autophagy; CMA+/CMA , CMA-active/-inactive
lysosomes; DAPI, 40,60-diamidino-2-phenylindole; inj., injections; LAMP-2A,
lysosomal-associated membrane protein type 2A; PQ, Paraquat; wks,
weeks.
and mounted specific CD4+ T-cell and antibody responses of
equal magnitude (160). On a clinical point of view, dermatitis
and renal damages were found to be diminished in MRL/lpr mice
that received P140 (75). The data described above, obtained in a
strong model of murine lupus and in patients with SLE, empha-
size the effectiveness potential of a unique peptide that targets
CMA and defective lysosomes to immunoregulate autoimmune
responses. We trust that this kind of strategy may be harnessed in
other pathological conditions in which reduction of CMA activity
would be desired.
Conclusion
ManipulatingMHCII antigen presentation of antigenic fragments
acquired via the endo-lysosomal pathway certainly represents an
efficient strategy to immunomodulate and selectively deviate the
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autoimmune response. The development of this approach relies
on a good knowledge of early processes subsequently leading
to autoantigen processing, loading, and presentation by MHCII
molecules. Greater understandings of the biogenesis and regu-
lation of lysosomes and late endosomal MHCII compartment
(MIIC), of their content in normal and variable pathological
environments using advanced proteomics approaches (nowadays
a technically unsolved challenge in the case of primary B lym-
phocytes), and of the role played by post-translational/epigenetic
changes that can dramatically affect antigen degradation, are a few
of some important research issues that deserve particular attention
in the future. The discovery of novel mechanisms that control
the lysosomal-autophagic pathways, notably in CMA, and their
possible deregulation in pathological settings are pivotal in this
frame. The P140/Lupuzor example demonstrates the feasibility
to control an extraordinary polymorphic autoimmune syndrome,
such as lupus, with a single and unique peptide, provided it is
used at early stages, upstream of the cascade of immune events.
With this information in mind, appropriate peptides and small
molecules that selectively target the endo-lysosomal route, lyso-
somes, and MIIC compartment could be poised to be tools of
choice to treat patients with efficacy and aminimumof safety risks
and deleterious side effects.
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